Iloprost has potent anti‐inflammatory properties on human monocyte‐derived dendritic cells

Abstract

In summary, our results provide evidence that iloprost profoundly affects the function of human myeloid DCs. Therefore, iloprost might also be a new therapeutical option for the treatment of asthma in humans.

Prostaglandin I2analogues enhance already exuberant Th17 cell responses in systemic sclerosis

“…Iloprost binds to several prostanoid receptors, with IP mediating most of its effects 29 32. When we blocked IP by CAY10449 antagonist the effects of iloprost were almost completely abolished, while no effects were observed when EP4 was blocked by AH23848 in both SSc and HD (figure 4A).…”

“…PGI 2 analogues downregulate lymphocyte adhesion to endothelial cells24 and inhibit the production of tumour necrosis factor α (TNFα) by human lymphocytes,25 26 monocytes27 28 and dendritic cells 20 29 30. Iloprost consistently decreases TNFα levels in BAL fluid of bleomycin-treated mice 31.…”

Effect of Prostaglandin I2 Analogs on Cytokine Expression in Human Myeloid Dendritic Cells via Epigenetic Regulation

“…Recently, PGI 2 is regarded as a potential treatment of asthma by their antiinflammatory effect in vitro (14,30) and in animal model (15). The antiinflammatory effect of PGI 2 analogs by altering the function of DCs has been revealed by our previous work using human plasmacytoid DCs (16) and by the work of Muller et al (31) using human monocyte-derived DCs (31). However, the effect of PGI 2 analogs on human mDCs is not elucidated.…”

Prostaglandin I2 Analogs Suppress Tumor Necrosis Factor α Production and the Maturation of Human Monocyte-Derived Dendritic Cells

“…40 In human studies, PGI 2 analogs have been shown to suppress TNF-α expression in human primary monocytes 41 and in plasmacytoid DCs. 11 Very recently, Muller et al 42 reported that iloprost inhibits inflammatory cytokine production by human MDDCs and induces the generation of regulatory T cells. The present study additionally demonstrated the role of PGI 2 analogs in regulating the expression of costimulatory molecules for the maturation of human MDDCs, supporting the current evidence for the candidacy of the PGI 2 analog as a modulatory agent in treating asthma.…”